Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease

Hideaki Fujiwara, Yoshinobu Maeda, Koichiro Kobayashi, Hisakazu Nishimori, Ken-ichi Matsuoka, Nobuharu Fujii, Eisei Kondo, Takehiro Tanaka, Lieping Chen, Miyuki Azuma, Hideo Yagita, Mitsune Tanimoto

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the role of the programmed death-1 (PD-1) pathway in chronic GVHD using a well-defined mouse model of B10.D2 (H-2d) donor to BALB/c (H-2d) recipients. PD-1 expression on allogeneic donor T cells was upregulated continuously in chronic GVHD development, whereas PD-L1 expression in host tissues was transiently upregulated and declined to basal levels in the late posttransplant period. Blockade of the PD-1 pathway by anti-PD-1, anti-PDL1, or anti-PD-L2 mAbs exacerbated clinical and pathologic chronic GVHD. Chimeric mice revealed that PD-L1 expression in host tissues suppressed expansion of IL-17+IFN-γ+T cells, and that PD-L1 expression on hematopoietic cells plays a role in the development of regulatory T cells only during the early transplantation period but does not affect the severity of chronic GVHD. Administration of the synthetic retinoid Am80 overcame the IL-17+IFN-γ+T cell expansion caused by PD-L1 deficiency, resulting in reduced chronic GVHD damage in PD-L1-/-recipients. Stimulation of the PD-1 pathway also alleviated chronic GVHD. These results suggest that the PD-1 pathway contributes to the suppression of Th17/Th1-mediated chronic GVHD and may represent a new target for the prevention or treatment of chronic GVHD.Copyright

Original languageEnglish
Pages (from-to)2565-2573
Number of pages9
JournalJournal of Immunology
Volume193
Issue number5
DOIs
Publication statusPublished - Sep 1 2014

Fingerprint

Graft vs Host Disease
Interleukin-17
T-Lymphocytes
Tissue Expansion
Cell Transplantation
Retinoids
Regulatory T-Lymphocytes
Cause of Death
Transplantation
Morbidity

ASJC Scopus subject areas

  • Immunology
  • Medicine(all)

Cite this

Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. / Fujiwara, Hideaki; Maeda, Yoshinobu; Kobayashi, Koichiro; Nishimori, Hisakazu; Matsuoka, Ken-ichi; Fujii, Nobuharu; Kondo, Eisei; Tanaka, Takehiro; Chen, Lieping; Azuma, Miyuki; Yagita, Hideo; Tanimoto, Mitsune.

In: Journal of Immunology, Vol. 193, No. 5, 01.09.2014, p. 2565-2573.

Research output: Contribution to journalArticle

Fujiwara, Hideaki ; Maeda, Yoshinobu ; Kobayashi, Koichiro ; Nishimori, Hisakazu ; Matsuoka, Ken-ichi ; Fujii, Nobuharu ; Kondo, Eisei ; Tanaka, Takehiro ; Chen, Lieping ; Azuma, Miyuki ; Yagita, Hideo ; Tanimoto, Mitsune. / Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease. In: Journal of Immunology. 2014 ; Vol. 193, No. 5. pp. 2565-2573.
@article{bec7832662d24ec1b3d26f9da0ab692e,
title = "Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease",
abstract = "Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the role of the programmed death-1 (PD-1) pathway in chronic GVHD using a well-defined mouse model of B10.D2 (H-2d) donor to BALB/c (H-2d) recipients. PD-1 expression on allogeneic donor T cells was upregulated continuously in chronic GVHD development, whereas PD-L1 expression in host tissues was transiently upregulated and declined to basal levels in the late posttransplant period. Blockade of the PD-1 pathway by anti-PD-1, anti-PDL1, or anti-PD-L2 mAbs exacerbated clinical and pathologic chronic GVHD. Chimeric mice revealed that PD-L1 expression in host tissues suppressed expansion of IL-17+IFN-γ+T cells, and that PD-L1 expression on hematopoietic cells plays a role in the development of regulatory T cells only during the early transplantation period but does not affect the severity of chronic GVHD. Administration of the synthetic retinoid Am80 overcame the IL-17+IFN-γ+T cell expansion caused by PD-L1 deficiency, resulting in reduced chronic GVHD damage in PD-L1-/-recipients. Stimulation of the PD-1 pathway also alleviated chronic GVHD. These results suggest that the PD-1 pathway contributes to the suppression of Th17/Th1-mediated chronic GVHD and may represent a new target for the prevention or treatment of chronic GVHD.Copyright",
author = "Hideaki Fujiwara and Yoshinobu Maeda and Koichiro Kobayashi and Hisakazu Nishimori and Ken-ichi Matsuoka and Nobuharu Fujii and Eisei Kondo and Takehiro Tanaka and Lieping Chen and Miyuki Azuma and Hideo Yagita and Mitsune Tanimoto",
year = "2014",
month = "9",
day = "1",
doi = "10.4049/jimmunol.1400954",
language = "English",
volume = "193",
pages = "2565--2573",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "5",

}

TY - JOUR

T1 - Programmed death-1 pathway in host tissues ameliorates Th17/Th1-mediated experimental chronic graft-versus-host disease

AU - Fujiwara, Hideaki

AU - Maeda, Yoshinobu

AU - Kobayashi, Koichiro

AU - Nishimori, Hisakazu

AU - Matsuoka, Ken-ichi

AU - Fujii, Nobuharu

AU - Kondo, Eisei

AU - Tanaka, Takehiro

AU - Chen, Lieping

AU - Azuma, Miyuki

AU - Yagita, Hideo

AU - Tanimoto, Mitsune

PY - 2014/9/1

Y1 - 2014/9/1

N2 - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the role of the programmed death-1 (PD-1) pathway in chronic GVHD using a well-defined mouse model of B10.D2 (H-2d) donor to BALB/c (H-2d) recipients. PD-1 expression on allogeneic donor T cells was upregulated continuously in chronic GVHD development, whereas PD-L1 expression in host tissues was transiently upregulated and declined to basal levels in the late posttransplant period. Blockade of the PD-1 pathway by anti-PD-1, anti-PDL1, or anti-PD-L2 mAbs exacerbated clinical and pathologic chronic GVHD. Chimeric mice revealed that PD-L1 expression in host tissues suppressed expansion of IL-17+IFN-γ+T cells, and that PD-L1 expression on hematopoietic cells plays a role in the development of regulatory T cells only during the early transplantation period but does not affect the severity of chronic GVHD. Administration of the synthetic retinoid Am80 overcame the IL-17+IFN-γ+T cell expansion caused by PD-L1 deficiency, resulting in reduced chronic GVHD damage in PD-L1-/-recipients. Stimulation of the PD-1 pathway also alleviated chronic GVHD. These results suggest that the PD-1 pathway contributes to the suppression of Th17/Th1-mediated chronic GVHD and may represent a new target for the prevention or treatment of chronic GVHD.Copyright

AB - Chronic graft-versus-host disease (GVHD) is a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation, but its pathogenesis remains unclear. We investigated the role of the programmed death-1 (PD-1) pathway in chronic GVHD using a well-defined mouse model of B10.D2 (H-2d) donor to BALB/c (H-2d) recipients. PD-1 expression on allogeneic donor T cells was upregulated continuously in chronic GVHD development, whereas PD-L1 expression in host tissues was transiently upregulated and declined to basal levels in the late posttransplant period. Blockade of the PD-1 pathway by anti-PD-1, anti-PDL1, or anti-PD-L2 mAbs exacerbated clinical and pathologic chronic GVHD. Chimeric mice revealed that PD-L1 expression in host tissues suppressed expansion of IL-17+IFN-γ+T cells, and that PD-L1 expression on hematopoietic cells plays a role in the development of regulatory T cells only during the early transplantation period but does not affect the severity of chronic GVHD. Administration of the synthetic retinoid Am80 overcame the IL-17+IFN-γ+T cell expansion caused by PD-L1 deficiency, resulting in reduced chronic GVHD damage in PD-L1-/-recipients. Stimulation of the PD-1 pathway also alleviated chronic GVHD. These results suggest that the PD-1 pathway contributes to the suppression of Th17/Th1-mediated chronic GVHD and may represent a new target for the prevention or treatment of chronic GVHD.Copyright

UR - http://www.scopus.com/inward/record.url?scp=84907021169&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907021169&partnerID=8YFLogxK

U2 - 10.4049/jimmunol.1400954

DO - 10.4049/jimmunol.1400954

M3 - Article

VL - 193

SP - 2565

EP - 2573

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 5

ER -